Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Research & Development (2020 - 2022)

Atea Pharmaceuticals has reported Research & Development over the past 3 years, most recently at $27.5 million for Q4 2022.

  • Quarterly results put Research & Development at $27.5 million for Q4 2022, down 52.36% from a year ago — trailing twelve months through Dec 2022 was $81.9 million (down 51.0% YoY), and the annual figure for FY2025 was $148.0 million, up 2.72%.
  • Research & Development for Q4 2022 was $27.5 million at Atea Pharmaceuticals, up from $4.9 million in the prior quarter.
  • Over the last five years, Research & Development for AVIR hit a ceiling of $57.8 million in Q4 2021 and a floor of $2.8 million in Q1 2020.
  • Median Research & Development over the past 3 years was $23.2 million (2021), compared with a mean of $23.9 million.
  • Biggest five-year swings in Research & Development: soared 841.9% in 2021 and later crashed 88.6% in 2022.
  • Atea Pharmaceuticals' Research & Development stood at $13.8 million in 2020, then surged by 317.53% to $57.8 million in 2021, then crashed by 52.36% to $27.5 million in 2022.
  • The last three reported values for Research & Development were $27.5 million (Q4 2022), $4.9 million (Q3 2022), and $19.9 million (Q2 2022) per Business Quant data.